Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.37 |
| ▸ | MARS1 | P56192 | 1/20 | 0.37 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | DHFR | P00374 | 1/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1676687 | 1.00 | DRD2 (0.41) | DRD2PLAUMRGPRX4POLBMAPT | |
| SCHEMBL1481757 | 0.93 | DRD2 (0.45) | DRD2POLBMAPTMARS1GCGR | |
| SCHEMBL1481756 | 0.93 | DRD2 (0.45) | DRD2POLBMAPTMARS1GCGR | |
| SCHEMBL1481857 | 0.93 | DRD2 (0.44) | DRD2PLAUPOLBMAPTP2RX3 | |
| SCHEMBL1481858 | 0.93 | DRD2 (0.44) | DRD2PLAUPOLBMAPTP2RX3 | |
| SCHEMBL1676387 | 0.93 | MARS1 (0.41) | MRGPRX4POLBMARS1SERPINE1GCGR | |
| SCHEMBL1676390 | 0.93 | MARS1 (0.41) | MRGPRX4POLBMARS1SERPINE1GCGR | |
| SCHEMBL1482394 | 0.92 | DRD2 (0.48) | DRD2PLAUPOLBMAPTMGLL | |
| SCHEMBL1482391 | 0.92 | DRD2 (0.48) | DRD2PLAUPOLBMAPTMGLL | |
| SCHEMBL1481631 | 0.88 | DRD2 (0.46) | DRD2PLAUPOLBMAPTMARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | TRANSTECH PHARMA, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| EP-1730118-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005080346-A1 | SUBSTITUTED AZOLE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | TRANSTECH PHARMA, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092553-A1 | Substituted Azole Derivatives, Compositions, and Methods of Use | PTPRO, PTPN5, PTPRE | DRD2 4873/4885PLAU 3307/4885MRGPRX4 2913/4885 |
| US-20050187277-A1 | Substituted azole derivatives, compositions, and methods of use | PTPRO, PTPN5, PTPRE | DRD2 4873/4885PLAU 3307/4885MRGPRX4 2913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.